Structure–activity relationship and docking studies of thiazolidinedione-type compounds with monoamine oxidase B

The neuroprotective activity of pioglitazone and rosiglitazone in the MPTP parkinsonian mouse prompted us to evaluate a set of thiazolidinedione (TZD) type compounds for monoamine oxidase A and B inhibition activity. These compounds were able to inhibit MAO-B over several log units of magnitude (82 nM to 600 μM). Initial structure–activity relationship studies identified key areas to modify the aromatic substituted TZD compounds. Primarily, substitutions on the aromatic group and the TZD nitrogen were key areas where activity was enhanced within this group of compounds.

NL-1 (1) docks with the aromatic moiety in the substrate cavity of human MAO-B.Figure optionsDownload as PowerPoint slide